INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 49m ago
HOUSE PTR8m ago
SEC 13F8m ago
ROBINHOOD CHAIN8m ago
SEC FORM 4/Derivative conversionVerified data

Dong Quehuong (Kathy) reported ETRA

Director, President & CEO · Electra Therapeutics, Inc. · Common Stock

Side
C
Value
—
Shares
455.5K
Price
—
Executed
Sep 21, 2026
Disclosed
Sep 21, 2026
Disclosure timeline0 days from execution to publication · legal deadline 2 business days
Sep 21 executedSep 21, 2026 disclosed

ETRA · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Derivative conversion — administrative, little informational value

  • Relative size+1 / 25

    No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 0 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · ETRA

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    PG
    Parry GrahamChief Scientific Officer
    ETRAElectra Therapeutics, Inc.
    Derivative conversion
    		C—
    85.5K sh
    		Sep 21, 2026Sep 21, 2026
    traded Sep 21, 2026
    		+0dSEC FORM 4

    Evidence

    9
    SN
    Stagliano NancyDirector
    ETRAElectra Therapeutics, Inc.
    Derivative conversion
    		C—
    255.6K sh
    		Sep 21, 2026Sep 21, 2026
    traded Sep 21, 2026
    		+0dSEC FORM 4

    Evidence

    9
    KS
    Koe Gary S.Chief Technical Officer
    ETRAElectra Therapeutics, Inc.
    Derivative conversion
    		C—
    63.7K sh
    		Sep 21, 2026Sep 21, 2026
    traded Sep 21, 2026
    		+0dSEC FORM 4

    Evidence

    9
    SN
    Stagliano NancyDirector
    ETRAElectra Therapeutics, Inc.
    Derivative conversion
    		C—
    255.6K sh
    		Sep 21, 2026Sep 21, 2026
    traded Sep 21, 2026
    		+0dSEC FORM 4

    Evidence

    9
    PG
    Parry GrahamChief Scientific Officer
    ETRAElectra Therapeutics, Inc.
    Derivative conversion
    		C—
    85.5K sh
    		Sep 21, 2026Sep 21, 2026
    traded Sep 21, 2026
    		+0dSEC FORM 4

    Evidence

    9
    KS
    Koe Gary S.Chief Technical Officer
    ETRAElectra Therapeutics, Inc.
    Derivative conversion
    		C—
    63.7K sh
    		Sep 21, 2026Sep 21, 2026
    traded Sep 21, 2026
    		+0dSEC FORM 4

    Evidence

    9
    DK
    Dong Quehuong (Kathy)Director, President & CEO
    ETRAElectra Therapeutics, Inc.
    Derivative conversion
    		C—
    455.5K sh
    		Sep 21, 2026Sep 21, 2026
    traded Sep 21, 2026
    		+0dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002153364-26-000004
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Sep 21, 2026
    Published
    Sep 21, 2026
    Ingested by INSIDER
    Nov 5, 02:16 UTC
    Last re-read
    Nov 5, 02:16 UTC

    Extracted facts

    Filer
    Dong Quehuong (Kathy)
    Role
    Director, President & CEO
    Transaction
    Derivative conversionAs filed: “C”
    Asset
    Electra Therapeutics, Inc.
    Ticker
    ETRA
    Shares
    455.5K
    Execution date (reported)
    Sep 21, 2026
    Owned after transaction
    455.5K shares
    Days from execution to publication
    0

    What this establishes

    Dong Quehuong (Kathy) filed this Form 4 reporting a derivative conversion of ETRA on Sep 21, 2026. It became public on Sep 21, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director, President & CEO
    Dong Quehuong (Kathy)cik:0002153364
    Issuer
    Electra Therapeutics, Inc.cik:0002088082

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.